Continuous Glucose Monitoring Market – By Component, By End Use – Global Forecast, 2025 – 2034

Continuous Glucose Monitoring Market Size

The global continuous glucose monitoring market size was estimated at USD 10.9 billion in 2024. The market is expected to grow from USD 12.4 billion in 2025 to USD 47.1 billion by 2034 at a CAGR of 16% during the forecast period. Continuous glucose monitoring (CGM) is an advanced diagnostic device, which is used to track blood glucose levels constantly throughout the day and night.
 

CGM systems use a small sensor which is inserted under the skin to measure interstitial glucose levels. These sensors are technologically advanced which are connected to a transmitter that sends glucose data to a display devices, such as smartphone, smartwatch, which allows users to view their glucose levels and pattern accordingly.
 

The increasing prevalence of diabetes is the key factor driving the growth of the market. For instance, according to a report from the World Health Organization (WHO), in 2022, nearly 830 million individuals suffer from diabetes globally, whereas majority of cases are from low and middle-income countries. Additionally, in 2021 diabetes led to 1.6 million deaths with 47% occurring before the age of 70 years. Thus, this statistics highlights the growing need for effective solutions such as continuous glucose monitoring devices, which help individuals to check their glucose level in body, improve their health, and tackle the global diabetes problem.
 

Further, the increasing government initiatives to generate awareness regarding diabetes play a vital role in shaping the continuous glucose monitoring market, by raising awareness towards diabetes monitoring and improving access to these devices. For instance, in the U.S. the Centers for Disease Control and Prevention (CDC) has implemented various programs to tackle diabetes.
 

The National Diabetes Prevention Program, launched in the U.S. aims to prevent or delay in type 2 diabetes. As part of this initiative, the CDC provides resource’s and information about diabetes management tools, such as CGM devices. Thus, technological innovations in CGM devices, and growing demand for continuous monitoring devices globally are fueling the demand for more effective and targeted CGM devices.
 

Continuous Glucose Monitoring Market Trends

• CGM devices are evolving with a significant technological advancements in recent years, accelerating the growth of the market. These innovations in CGM have increased the accuracy, convenience and experience of users of CGM devices, making them more attractive to both patients and healthcare providers.
   
• The improvement in sensor accurateness and longevity is the major technological advancement seen in CGM devices. Modern sensors offer prolonged wear times and enhanced stability. For instance, Stelo Glucose Biosensor, by Dexcom, offers a 15 day wear and with a 12 hour of grace period.
   
• In addition, to this incorporation of smart devices and data sharing resources has improved the functionality of CGM devices. Thus, many modern CGM devices transmit real-time glucose level data directly to smartphone, smartwatches, and other connected devices. This makes it more convenient for users to monitor and track their glucose levels and also share data directly to their healthcare providers.
• For instance, the Freestyle Libre 2 system provides optional real time alarms on smartphones, alerting individuals about their glucose levels.
   
• Further, artificial intelligence in healthcare and machine learning are being integrated into CGM systems, which offers personalized insights and analytical capabilities. These technologically advanced analytics help individuals and healthcare professionals to identify the patterns, can also assist them to predict the future glucose levels and trends, and accordingly help to make decisions, thus contributing to the market growth.
   

Trump Administration Tariffs

• Tariffs on imports from key manufacturing countries, such as China, are anticipated to increase production costs for continuous glucose monitoring (CGM) devices. These tariffs are expected to affect essential components like sensors, transmitters, receivers, and electronic chips used in CGM devices. As many CGM manufacturers rely on cost-effective and high-quality Chinese suppliers, higher tariffs are likely to disrupt the global supply chain significantly.
   
• In response to these tariffs, companies in the CGM market are expected to reconsider their sourcing and manufacturing strategies to reduce dependency on a single geographic region. Manufacturers may shift operations to alternative markets, such as India, Malaysia, Vietnam, or Eastern Europe, to mitigate risks and costs.
   
• In the short term, companies are likely to face challenges, including longer delivery times, increased production costs, and potential shortages of critical components required for CGM devices. These disruptions are expected to impact diabetes patients who rely on real-time glucose tracking.
   
• Furthermore, these global trade shifts are anticipated to drive companies to invest in localized manufacturing and R&D facilities, particularly in North America and Europe, to enhance supply chain resilience and ensure regulatory compliance.
   

Continuous Glucose Monitoring Market Analysis

Based on component, the market is bifurcated into transmitters, sensors, and receivers. The global market accounted for USD 10.9 billion in 2024. The sensors segment held revenues of USD 5.5 billion in the year 2024 and the segment is poised to show a significant growth rate of 16.1% during the forecast period.
 

• The continuous advancement in sensor technology particularly in terms of its  accuracy and reliability, is significantly propelling the growth of the market.
   
• Modern sensors have significantly improved their accuracy, with some of the devices achieving a mean absolute relative difference (MARD) lower than 10%. For example, a study published in National Institutes of Health (NIH) in 2023 reported that Dexcom has 8.2% of MARD, whereas 9.7% of MARD in Abbott’s Freestyle Libre. This accuracy has led to the better adoption of CGM systems among the individuals.
   
• In addition to this, small sensors have made CGM devices more comfortable for the users. For instance, the latest innovation in CGM sensors is of Dexcom G7, which is about the size of penny and can be wore under an individual’s clothing. This small size has improved the comfort for the users and has allowed sensors to last for up to 10 days for continuous use before requiring replacements.
   
• Further, many new advanced biosensors can track more than glucose. The advanced sensors can also measure ketones or lactate in individuals body. This gives a better overall picture of metabolic health and helps users to manage their diabetes more accurately. Thus, this advancement is accelerating the market growth.
   

Based on end use, the continuous glucose monitoring market is bifurcated into hospitals, home care settings, diagnostic centres and clinics, and other end users. The home care settings segment held a significant revenue of USD 8.8 billion in 2024 with a revenue share of 81%.
 

• The growing prevalence of diabetes globally, is creating a demand for effective continuous glucose monitoring solutions for home use. Advanced CGM devices helps patients by providing real time data and alerts and also track glucose levels, thus making homecare a better and convenient option for the patients.
   
• In addition to this, the introduction of new innovated technologies in CGM devices has enhanced their accuracy, comfort and ease of use, which is encouraging more individuals to adopt them.
   
• Similarly, many CGM devices has ability to connect to smartphones and other digital devices or apps, which makes it easier to track the data and to share it with healthcare providers.
   
• For example, Abbott Freestyle Libre 2, Dexcom G7, and Abbott Freestyle Libre 3, are designed for home use, with user guides, app support, and phone assistance to help patients.
   
• Furthermore, due to the COVID-19 pandemic the adoption of homebased healthcare solutions such as CGM devices has further increased. During pandemic outbreak, people preferred to avoid hospital visits and limit the exposure to healthcare settings. As a result, CGM systems have become even more important for managing chronic conditions such as diabetes at home, which is contributing to the market growth.
   

The North America continuous glucose monitoring market accounted for 5.1 billion revenues in 2024 forecasted to reach USD 22.6 billion by 2034. The U.S. dominated the North America market with the largest revenue of USD 4.9 billion in 2024.
 

• The rising prevalence of diabetes in the U.S., is accelerating the demand for the CGM devices.
   
• For instance, in 2021, as per the data from the Centers for Disease Control and Prevention (CDC), approximately 38.4 million individuals in U.S. suffered from diabetes, out of which 90-95% of individuals suffered from type 2 diabetes.
   
• The market has also expanded due to favorable reimbursement policies. Medicare has made its coverage for CGM devices more inclusive, increasing system accessibility to a wider population. From January 2023, the Centres for Medicare & Medicaid Services (CMS) broadened the scope of CGM device coverage to-encompass people with diabetes who take insulin or have had problematic hypoglycemia in the past.
   

Europe: The continuous glucose monitoring market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The growth of market is anticipated to be bolstered by the rising cases of diabetes across the UK. For instance, according to the British Diabetic Association, about 5.8 million people in the UK were suffering with diabetes , additionally, nearly 1.3 million people had type 2 diabetes.
   
• Further, the growth of market in this region is anticipated to be strengthened by the UK governments commitment towards tracking diabetes via initiatives such as public health campaigns and guidelines that promotes the healthier lifestyle, thus propelling industry expansion.
   
• In addition, the increasing spending on diabetes is also contributing to the use of CGM devices in the UK. For example, the NHS spends around USD 10.5 billion on diabetes, which is about 10% of its total budget according to European Federation of Pharmaceutical Industries and Associations.
   

Asia pacific: Japan continuous glucose monitoring market is poised for substantial growth between 2025 – 2034.
 

• Japan has one of the fastest aging populations globally. As per the 2023 estimates of the World Economic Forum, Japan has around 36.25 million people aged 65 years and above, which leads to one-third of the entire Japanese population.
   
• The rising incidence of diabetes in Japan is accelerating the market growth. For instance, according to the report from Internation Diabetes Federation (IDF), in 2021, 11 million individuals were affected with diabetes, which is 11.8% of the total population.
   
• Thus, this demographic shift has created awareness among the healthcare providers and policy makers to implement effective strategies to overcome diabetes and its related health conditions.
   
• Further, through programs such the ‘Health Japan 21’ campaign, which aims to reduce the number of lifestyle-related diseases, the Japanese government is raising awareness regarding physical health and its monitoring.
   

Middle East and Africa: The continuous glucose monitoring market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia’s advance healthcare infrastructure and rising investment in advanced healthcare technologies create opening for the development and adoption of advanced CGM devices tailored to the country’s patient specific needs.
   
• Moreover, there is a rise in health awareness programs in Saudi Arabia, such as Saudi National Diabetes Screening Program, that focuses on chronic disease management like diabetes and emphasizes on its prevention and treatment. Thus, CGM devices are playing a key role in promoting the early interventions and educating the users on adopting the healthier lifestyle habits to prevent the chronic illness and enhance overall well-being.
   
• In addition, Vision 2030’s focus on healthcare modernization is boosting investments in continuous glucose monitoring, supported by the need for advanced devices for managing diabetes.
   

Continuous Glucose Monitoring Market Share

The top 4 players of the market account for approximately 70% of the market share which includes companies such as Abbott Laboratories, Dexcom, Medtronic, and Senseonics among others. These companies maintain their dominance in the market through innovative product launches, extensive distribution networks and strong regulatory approval.
 

Moreover, strategic partnerships with research institutes and government agencies play a primary role in advancing the development of advanced continuous glucose monitoring and getting the necessary permits. The development of public awareness about chronic diseases such as diabetes and its health impact through the social media platform is encouraging more individuals to seek the treatment. This is enabling market players to strengthen their position in this growing sector.
 

Continuous Glucose Monitoring Market Companies

Some of the eminent market participants operating in the continuous glucose monitoring industry include:

• Abbott Laboratories
• A. Menarini Diagnostics
• Dexcom
• i-SENS
• F. Hoffmann-La Roche
• Med Trust
• Medtronic
• Medtrum Technologies
• Senseonics
• Sinocare
• Zhejiang POCTech
   
• Abbott Laboratories has strong product portfolio leading to larger adoption and significant market expansion. Abbott provides a diverse range of products pertaining to CGM such as FreeStyle Libre 2, FreeStyle Libre 3, among others.
   
• Dexcom invests in research and development, fostering innovation and growth. The company continuously evolves with newest advancement in CGM devices.
   
• Medtronic has strong geographical presence which enables it to enhance its market reach. Medtronic operates in more than 150 countries thus comprising of a robust distribution network.
   

Continuous Glucose Monitoring Industry News:

• In July 2024, Roche announced the CE Mark approval for its Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution. This approval expanded the company’s reputation in the market.
   
• In June 2024, Abbott announced U.S. Food and Drug Administration (FDA) has approved its two new over-the-counter CGM systems, Lingo and Libre Rio, based on FreeStyle Libre continuous glucose monitoring technology. This approval enhanced the company’s competitiveness in the market.
   
• In March 2024, Dexcom announced the U.S. FDA approval of its first over-the-counter CGM system, Stelo. This CGM is the first glucose biosensor that doesn’t require a prescription. The device is expected to benefit patients who have recently been diagnosed with diabetes and are not taking insulin prescriptions.
   
• In January 2024, Medtronic plc reported receiving CE Mark approval for the MiniMed 780G system which features Simplera Syn. With a fingerstick-free design and no overtape required, the CGM enhances user experience while maintaining glucose monitoring accuracy and reliability due to its ease of insertion and smaller size.
   

The continuous glucose monitoring market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Component

• Transmitters
• Sensors
• Receivers

Market, By End Use

• Hospitals
• Home care settings
• Diagnostic centres and clinics
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Sweden
  • Russia
  • Denmark
  • Finland
  • Norway
  • Poland
  • Switzerland
  • Belgium
  • Lithuania
  • Latvia
  • Estonia
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Taiwan
  • Indonesia
  • Vietnam
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Chile
  • Peru
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Turkey
  • Egypt
  • Israel
  • Kuwait
  • Qatar